Back to Search
Start Over
The Alzheimer's disease-linked protease BACE2 cleaves VEGFR3 and modulates its signaling
- Source :
- Journal of Clinical Investigation. August 15, 2024, Vol. 134 Issue 16
- Publication Year :
- 2024
-
Abstract
- The [beta]-secretase [beta]-site APP cleaving enzyme (BACE1) is a central drug target for Alzheimer&apos;s disease. Clinically tested, BACE1-directed inhibitors also block the homologous protease BACE2. Yet little is known about physiological BACE2 substrates and functions in vivo. Here, we identify BACE2 as the protease shedding the lymphangiogenic vascular endothelial growth factor receptor 3 (VEGFR3). Inactivation of BACE2, but not BACE1, inhibited shedding of VEGFR3 from primary human lymphatic endothelial cells (LECs) and reduced release of the shed, soluble VEGFR3 (sVEGFR3) ectodomain into the blood of mice, nonhuman primates, and humans. Functionally, BACE2 inactivation increased full-length VEGFR3 and enhanced VEGFR3 signaling in LECs and also in vivo in zebrafish, where enhanced migration of LECs was observed. Thus, this study identifies BACE2 as a modulator of lymphangiogenic VEGFR3 signaling and demonstrates the utility of sVEGFR3 as a pharmacodynamic plasma marker for BACE2 activity in vivo, a prerequisite for developing BACE1- selective inhibitors for safer prevention of Alzheimer&apos;s disease.<br />Introduction Alzheimer's disease (AD) is the most common neurodegenerative disorder. Effective therapeutic or preventive approaches for this deadly disease are lacking. A central drug target for AD is the transmembrane [...]
Details
- Language :
- English
- ISSN :
- 00219738
- Volume :
- 134
- Issue :
- 16
- Database :
- Gale General OneFile
- Journal :
- Journal of Clinical Investigation
- Publication Type :
- Academic Journal
- Accession number :
- edsgcl.808510042
- Full Text :
- https://doi.org/10.1172/JCI170550